SRDX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Surmodics to GTCR
MONSEY, N.Y., May 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $43.00 per share in cash for which Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics”) has agreed to be sold to GTCR, a leading private equity firm.
- MONSEY, N.Y., May 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $43.00 per share in cash for which Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics”) has agreed to be sold to GTCR, a leading private equity firm.
- The sales price is far below the price targets for Surmodics of at least two Wall Street analysts (source: TipRanks).
- On May 29, 2024, Surmodics announced that it had agreed to be sold to GTCR for $43.00 per share in cash.
- “We are investigating whether the Surmodics Board of Directors acted in the best interests of Surmodics shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter.